Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-19-061091

Chief Executive Officer acquired 8,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2019-12-16 Option exercise +8,000 $1.81 $14,480 172,320 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2019-12-16 Option exercise · Stock Option (Right to Buy) −8,000 195,058 D
Loading xslF345X03/doc4.xml…